Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique. (CHLOR-DETOX)

Effects of Oral Intake of the Probiotic Limosilactobacillus Reuteri on Plasma Chlordecone (Kepone) Concentrations (Chlordeconemia) in Individuals Environmentally Exposed to the Organochlorine Pesticide in Martinique : an Exploratory Pilot Study

The CHLOR-DETOX study is a single-centre, double-blind, prospective, interventional, controlled, exploratory pilot study on subjects environmentally exposed to the organochlorine pesticide (kepone or chlordecone, CLD) in the French Caribbean (Martinique island). To our best knowledge, it is the first clinical trial in such subjects evaluating the potential effect of oral probiotic intake (Limosilactobacillus reuteri) on the reduction of CLD plasma levels (chlordeconemia) and fecal excretion, thus concurring to the reduction of CLD toxicity in study subjects.

Study Overview

• Status: Not yet recruiting
• Conditions: Chlordecone (Kepone) Toxicity
• Intervention / Treatment: Other: Placebo; Dietary supplement: Limosilactobacillus reuteri

Detailed Description

The research question focuses on the ability of the probiotic Limosilactobacillus reuteri Gastrus (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475 from the BioGaia® company) to reduce CLD toxicity in subjects exposed to this pesticide. In particular, the investigators are interested in whether the oral prescription of Limosilactobacillus reuteri reduces plasma levels of CLD by increasing the fecal excretion of the deconjugated form of CLD. This research hypothesis is based on the presence of a hydrolase activity (glucuronidase) in Limosilactobacillus reuteri that allows the deconjugation of glucuronide derivatives (De Boever et al 2000; Cardona et al. 2002; Martoni et al 2008). Limosilactobacillus reuteri is the probiotic with the highest hydrolase activity. The combination of Limosilactobacillus reuteri DSM 17938 and Limosilactobacillus reuteri ATCC PTA 6475 (BioGaia® Gastrus) is currently the best possible formulation for optimal hydrolase activity (unpublished data from BioGaia® laboratory). The investigators also hypothesize that the increase in CLD elimination by the digestive tract through the use of Limosilactobacillus reuteri avoids the appearance of side effects encountered during the prolonged use of classical bile salt sequestrants (e.g. QUESTAN).

The effects of oral prescription of Limosilactobacillus reuteri on plasma levels and faecal concentrations of CLD will be compared with a control group under placebo.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: SEBASTIEN CAVALINI; Phone Number: +596 596 592 696; Email: sebastien.cavalini@chu-martinique.fr
• Study Contact Backup: Name: CORINE CARPIN; Phone Number: +596 596 592 696; Email: corine.carpin@chu-martinique.fr

Study Locations

• Martinique
  • France
    • Fort-de-France, France, Martinique, 97261
      • Centre Hospitalier Universitaire de Martinique - Hôpital Pierre ZOBDA QUITMAN
      • Contact: SEBASTIEN CAVALINI; Phone Number: +596 596 592 696; Email: sebastien.cavalini@chu-martinique.fr
      • Contact: CORINE CARPIN; Phone Number: +596 596 592 696; Email: corine.carpin@chu-martinique.fr
      • Principal Investigator: Dabor RESIERE, Professor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female, 18 years of age or older
• Seen in clinical toxicology consultation at the CHU of Martinique during the study period
• With an initial chlordeconemia > 1μg/L on a test less than 1 month old at the time of study inclusion
• Affiliated to a social security scheme
• Having received informed information on research
• Having freely given written and informed consent to participate in the research

Exclusion Criteria:

• History of cancer
• Recent infections less than 6 months old
• Known digestive diseases: chronic diarrhoea, ulcerative colitis, Crohn's disease, pancreatitis
• Digestive procedures less than 6 months old.
• Intrahepatic cholestasis less than 6 months old
• Extrahepatic cholestasis less than 6 months old
• Use of cholestyramine or ursodeoxycholic acid in the previous 3 months
• Consumption of food (non-ordinary yoghurt, etc.) or supplements (tablets, drops, capsules, etc.) containing L. reuteri or any other probiotic within the previous 2 weeks.
• Antibiotics taken in the previous 4 weeks.
• Immune deficiency secondary to a pathology (lymphoma, leukaemia) or medical treatment (immunosuppressant, corticoid, chemotherapy).
• Women who are unable to obtain contraception during the trial

• Persons referred to in articles L.1121-5, L.1121-7, L. 1121-8 of the Public Health Code:

  • Pregnant woman, parturient or breastfeeding mother
  • Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Persons deprived of their liberty by a judicial or administrative decision,
  • Persons staying in a health or social care institution for purposes other than research
• Persons subject to psychiatric care under Articles L. 3212-1 and L. 3213-1 of the Public Health Code.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control group; The control group will receive daily a placebo capsule per os at mealtime (just before or after) for a period of 6 months	Other: Placebo; The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
Experimental: Experimental group; The experimental group will receive daily per os one capsule of BioGaia® Gastrus probiotic (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) dosed at 108 colony forming units (CFU)/day (distributed by the laboratory PEDIACT France), taken at mealtime (just before or after) for a period of 6 months	Dietary supplement: Limosilactobacillus reuteri; The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10^8 CFU*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour. *Colony forming Unit; Other Names: BioGaïa® Gastrus

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chlordeconemia	Chlordeconemia measured by a gas chromatography/mass spectrometry (GC/MS) technique expressed in μg/L (analytical detection limit LDD of 0.05 μg/L - quantification limit LDQ of 0.1 μg/L) The relative change in chlordeconemia between T0 and T6 months will be compared between the group of patients treated with the BioGaia® Gastrus probiotic and the group of patients treated with placebo. This relative variation will be calculated as the ratio of the difference in chlordeconemia T0 -T6mois to the initial chlordeconemia at T0.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chlordeconemia	Chlordeconemia measured by a gas chromatography/mass spectrometry (GC/MS) technique expressed in μg/L (analytical detection limit LDD of 0.05 μg/L - quantification limit LDQ of 0.1 μg/L The relative change in chlordeconemia between T0 and T3months will be compared between the BioGaia® Gastrus probiotic treated group and the placebo treated group. This relative variation will be calculated as the ratio of the difference in chlordeconemia T0 -T3months to the initial chlordeconemia at T0.	3 months
Variation of chlordeconemia	The relative variation of chlordeconemia from T0 to T6 months in each group of patients (probiotic group, placebo group) will be described. The plasma half-life values of CLD, expressed in months, will be determined for each group.	6 months
concentration of CLD in the stool	The concentration of CLD in the stool at 3 months (T3 months) and 6 months (T6 months) will be measured using the same method described in the primary outcome (GC/MS technique). The relative changes in stool CLD concentration between T0 and T3mois and T0 and T6mois will be compared between the BioGaia® Gastrus probiotic treated group and the placebo treated group.	6 months
Variation of chlordecone concentration in stool	- The relative change in stool CLD concentration from T0 to T6months within each patient group (probiotic group, placebo group) will be described	6 months
Plasma total cholesterol concentrations	Plasma total cholesterol concentrations, measured by the reference technique (ultracentrifugation followed by heparin-manganese precipitation and then quantification by the Abell-Kendall method) at T0 , T3 months and T6 months will be described. The relative variations of plasma total cholesterol concentrations between T0 and T3months and T0 and T6months will be compared between the group of patients treated with the BioGaia® Gastrus probiotic and the group of patients treated with placebo.	6 months
Clinical tolerance to BioGaia® Gastrus probiotic or placebo	Treatments will be assessed by adverse event reporting and based on a standardised and internationally recognised toxicity table for adults. This tolerance will be assessed by a telephone interview at T1 month, T2 months, T4 months and T5 months, as well as during face-to-face follow-up visits at T3months and T6months .	6 months

Collaborators and Investigators

• Sponsor: University Hospital Center of Martinique
• Collaborators: University Hospital, Limoges; Reims University Hospital; BioGaia AB; Regional Health Agency, Martinique; Biological Resource Centre, Martinique
• Investigators: Principal Investigator: DABOR RESIERE, Professor, University Hospital of Martinique

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2024
• Primary Completion (Estimated): April 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: August 30, 2023
• First Submitted That Met QC Criteria: August 30, 2023
• First Posted (Actual): September 7, 2023

Study Record Updates

• Last Update Posted (Actual): February 21, 2024
• Last Update Submitted That Met QC Criteria: February 19, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Probiotics; Chlordecone toxicity; Gut elimination; entero-hepatic cycle; plasma level concentration
• Other Study ID Numbers: 21_RIPH3-08; 2021-A02293-38 (Other Identifier: French National Medicines and Health Products safety Agency)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No